UY36308A - Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso - Google Patents

Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso

Info

Publication number
UY36308A
UY36308A UY0001036308A UY36308A UY36308A UY 36308 A UY36308 A UY 36308A UY 0001036308 A UY0001036308 A UY 0001036308A UY 36308 A UY36308 A UY 36308A UY 36308 A UY36308 A UY 36308A
Authority
UY
Uruguay
Prior art keywords
hat
methods
acetiltranspherases
spirocycles
histone
Prior art date
Application number
UY0001036308A
Other languages
English (en)
Inventor
Mcclellan William
Michaelides Michael
Hansen Todd
Da Yujia
Zhu Guidong
Frey Robin
Gong Jane
Penning Thomas
Curtin Michael
Clark Richard
Torrent Maricel
Mastracchio Anthony
Edward A Kesicki
Arthur F Kluge
Michael A Patane
H Van Drie John Jr
Ji Zhiqin
Chunqiu C Lai
Wang Ce
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of UY36308A publication Critical patent/UY36308A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos con la estructura de Fórmula (IX): o un estereoisómero, tautómero o sal farmacéuticamente aceptable del mismo, en donde R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, e y tienen los valores definidos en la presente. Composiciones farmacéuticas que comprenden dichos compuestos y métodos para el tratamiento de diversas condiciones o enfermedades relacionadas con las HAT, que incluyen el cáncer, mediante la administración de tales compuestos.
UY0001036308A 2014-09-18 2015-09-18 Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso UY36308A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/086792 2014-09-18
US201562157253P 2015-05-05 2015-05-05

Publications (1)

Publication Number Publication Date
UY36308A true UY36308A (es) 2016-04-29

Family

ID=54207822

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036308A UY36308A (es) 2014-09-18 2015-09-18 Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso

Country Status (5)

Country Link
US (3) US20160235716A1 (es)
AR (1) AR101986A1 (es)
TW (1) TW201623251A (es)
UY (1) UY36308A (es)
WO (1) WO2016044770A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190270797A1 (en) 2016-07-25 2019-09-05 Epizyme, Inc. Crebbp related cancer therapy
US10981900B2 (en) * 2017-02-28 2021-04-20 Medshine Discovery Inc. Spiro compound and use thereof
EP3596117A4 (en) * 2017-03-17 2021-01-13 The Johns Hopkins University TARGETED EPIGENETIC THERAPY AGAINST THE DISTAL EXPRESSION REGULATORY ELEMENT OF TGFB2
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
TW201922721A (zh) 2017-09-07 2019-06-16 英商葛蘭素史克智慧財產發展有限公司 化學化合物
EP3752250B1 (en) 2018-02-16 2022-08-03 Constellation Pharmaceuticals, Inc. P300/cbp hat inhibitors
LT3752497T (lt) 2018-02-16 2024-09-25 Constellation Pharmaceuticals, Inc. P300/cbp hat inhibitoriai
WO2019201291A1 (zh) 2018-04-20 2019-10-24 中国科学院上海药物研究所 组蛋白乙酰转移酶(hat)抑制剂及其用途
WO2019236988A1 (en) * 2018-06-08 2019-12-12 Carnegie Mellon University Protein and peptide purification methods
CN108727309B (zh) * 2018-06-20 2023-04-07 天津全和诚科技有限责任公司 一种3-氧杂环丁烷羧酸的合成方法
CA3103711A1 (en) * 2018-07-12 2020-01-16 UCB Biopharma SRL Spirocyclic indane analogues as il-17 modulators
EP3873898A4 (en) * 2018-11-02 2022-11-30 Dana-Farber Cancer Institute, Inc. DEVELOPMENT AND USES OF ACETYLATION RECORDER INHIBITORS
CN111217802B (zh) * 2018-11-27 2021-10-08 海创药业股份有限公司 一类组蛋白乙酰化酶p300抑制剂及其用途
LT3930838T (lt) 2019-02-27 2024-09-10 Constellation Pharmaceuticals, Inc. N-(piridinil)acetamido dariniai kaip p300/cbp hat inhibitoriai ir jų naudojimo būdai
WO2020204112A1 (ja) 2019-04-01 2020-10-08 日産化学株式会社 ピリダジノン化合物及び除草剤
CN111732545B (zh) * 2020-06-08 2023-03-10 华侨大学 一种2,3-二氢螺[咪唑-4,1′-茚]类化合物及其制备方法
US20240122941A1 (en) * 2020-12-25 2024-04-18 National Cancer Center Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer
US11911367B2 (en) * 2021-03-15 2024-02-27 Regents Of The University Of Minnesota Methods for treating cancer
TW202412775A (zh) * 2022-08-10 2024-04-01 日商住友製藥股份有限公司 以四級碳置換之三級醯胺衍生物
CN115894141B (zh) * 2022-10-13 2023-12-22 贺州学院 酰基茚烷类衍生物的合成方法
GB202302941D0 (en) 2023-02-28 2023-04-12 Tocris Cookson Ltd Proteolysis-targeting chimeras
US11926601B1 (en) 2023-08-29 2024-03-12 King Faisal University 5-spiro 9,10-dihydroanthracene derivative of imidazolidine-2,4-dione as an anticancer agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005670B2 (en) * 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies

Also Published As

Publication number Publication date
US20180071262A1 (en) 2018-03-15
US20180193315A1 (en) 2018-07-12
WO2016044770A1 (en) 2016-03-24
TW201623251A (zh) 2016-07-01
AR101986A1 (es) 2017-01-25
US20160235716A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
UY36308A (es) Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
ECSP16067692A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CR20180356A (es) Un medicamento caracterizado por combinar un inhibidor de la endonucleasa cap-dependiente del virus de la influenza y un fármaco anti-influenza
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
UY37842A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
AR103680A1 (es) Inhibidores selectivos de bace1
UY37843A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
CR20170003A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
UY36124A (es) Derivados de carboxamida
UY36123A (es) Derivados de carboxamida
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
ECSP18056196A (es) Derivados de indano
CL2016002870A1 (es) Derivados bicíclicos y composición farmacéutica que incluye los mismos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220705